Aequus Pharmaceuticals Announces Executive Appointments
experience in the pharmaceutical industry, with a track record leading multinational organizations. He is a
recognized leader in life cycle management with a background in both branded and generic pharmaceuticals. Most recently as the Global Head of Brand Maximization and Life Cycle Strategy with Novartis, he was responsible for leading the organization through the recent patent losses of both Diovan and Gleevec, generating incremental value of over $400 million. Ball also led the global strategy for life-cycle management across the entire Novartis portfolio with total revenues up to $42 billion.